Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.

[1]  G. Fonarow,et al.  The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. , 2003, Reviews in cardiovascular medicine.

[2]  Peter C Austin,et al.  Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.

[3]  J. Ouyang,et al.  Tolvaptan (OPC-41061), a V2 vasopressin receptor antagonist, protects against the decline in renal function observed with loop diuretic therapy , 2003 .

[4]  Eliot G. Peyster,et al.  Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). , 2003, Journal of the American College of Cardiology.

[5]  C. O'connor,et al.  Vasopressin: a new target for the treatment of heart failure. , 2003, American heart journal.

[6]  M. Gheorghiade,et al.  Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial , 2003, Circulation.

[7]  C. O'connor,et al.  Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. , 2003, The American journal of cardiology.

[8]  A. Tuttolomondo,et al.  Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. , 2003, American heart journal.

[9]  C. O'connor,et al.  Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. , 2003, American heart journal.

[10]  L. Rydén,et al.  Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. , 2003, Journal of the American College of Cardiology.

[11]  S. Goldsmith.  Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure. , 2002, Congestive heart failure.

[12]  J. Ouyang,et al.  Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination , 2002 .

[13]  M. Cuffe.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. , 2002, JAMA.

[14]  H Ector,et al.  Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. , 2001, The New England journal of medicine.

[15]  P. Lapuerta,et al.  A health perception score predicts cardiac events in patients with heart failure: results from the IMPRESS trial. , 2001, Journal of cardiac failure.

[16]  Ame,et al.  PROGNOSTIC IMPORTANCE OF ELEVATED JUGULAR VENOUS PRESSURE AND A THIRD HEART SOUND IN PATIENTS WITH HEART FAILURE , 2001 .

[17]  G. Fonarow,et al.  Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. , 2000, American heart journal.

[18]  Y. Yamamura,et al.  Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. , 2000, The Journal of pharmacology and experimental therapeutics.

[19]  M. Domanski,et al.  Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. , 1999, Circulation.

[20]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[21]  J. Croft,et al.  Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. , 1999, American heart journal.

[22]  T Yamashita,et al.  OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. , 1998, The Journal of pharmacology and experimental therapeutics.

[23]  S. Goldstein,et al.  Relation of left ventricular chamber shape in patients with low (< or = 40%) ejection fraction to severity of functional mitral regurgitation. , 1995, The American journal of cardiology.

[24]  W. Stevenson,et al.  Sudden Death Prevention in Patients With Advanced Ventricular Dysfunction , 1993, Circulation.

[25]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[26]  G. Francis,et al.  Arginine vasopressin and the renal response to water loading in congestive heart failure. , 1986, The American journal of cardiology.

[27]  J. Cohn,et al.  Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[28]  R. A. Johnson,et al.  Heart failure in outpatients: a randomized trial of digoxin versus placebo. , 1982, The New England journal of medicine.

[29]  T. Berl,et al.  Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. , 1981, The New England journal of medicine.